BIND Biosciences is a biopharmaceutical company developing therapeutic targeted nanoparticles capable of profoundly improving patients' lives by concentrating drugs in the target tissue while minimizing systemic exposure. The company's technology platform provides a unique ability to produce precise and reproducible nanoparticles optimized for their specific therapeutic application. BIND's scientific founders, Professors Robert Langer of MIT and Omid Farokhzad of Harvard Medical School are leaders in the fields of drug delivery and nanotechnology with a strong track record of innovation and technology commercialization.

Flagship Managing Partner Noubar Afeyan is on the Board of Directors.

www.bindbio.com